Patents by Inventor Jeffrey Su
Jeffrey Su has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210286776Abstract: The present disclosure provides apparatus, systems, and methods for crowdsourcing domain specific intelligence. The disclosed crowdsourcing mechanism can receive domain specific intelligence as a data processing rule module. For example, a data analytics system can request a crowd of software developers to provide a data processing rule module tailored to process a particular type of information from a particular domain. When the data analytics system receives the data processing rule module from one of the software developers for the particular domain, the data analytics system can use the received data processing rule module to process information associated with the particular domain.Type: ApplicationFiled: October 26, 2020Publication date: September 16, 2021Applicant: FACTUAL INC.Inventors: Jeffrey SU, Boris SHIMANOVSKY
-
Patent number: 10817482Abstract: The present disclosure provides apparatus, systems, and methods for crowdsourcing domain specific intelligence. The disclosed crowdsourcing mechanism can receive domain specific intelligence as a data processing rule module. For example, a data analytics system can request a crowd of software developers to provide a data processing rule module tailored to process a particular type of information from a particular domain. When the data analytics system receives the data processing rule module from one of the software developers for the particular domain, the data analytics system can use the received data processing rule module to process information associated with the particular domain.Type: GrantFiled: March 14, 2014Date of Patent: October 27, 2020Assignee: FACTUAL INC.Inventors: Jeffrey Su, Boris Shimanovsky
-
Patent number: 10609534Abstract: A processing device executing a data feed service performs a first query of a repository of data feed entries. The processing device determines, based on the first query, that a first data feed entry comprises a schedule to provide data from a first data feed of a first data source to a first device in an upcoming first time period, wherein the first data feed entry identifies the first data source, a first data type associated with the first data source, the first time period, and the first device. The processing device sends, to the first data source, a request for first data having the first data type and then receives the first data. The processing device sends the first data to the first device in the first time period.Type: GrantFiled: August 23, 2016Date of Patent: March 31, 2020Assignee: Ayla Networks, Inc.Inventors: Sudha Sundaresan, Vadym Byelov, Sulagna Bal, Jeffrey Su
-
Publication number: 20170247458Abstract: There is disclosed a chimeric cetuximab-like monoclonal antibody (CMAB009 mAb) having at least 80% NANA glycosylation terminal sialic acid at an N-glycosylation site Asn297 and a glycosylation pattern of Gal-?(2,3/6)-Gal. The disclosed CMAB009 monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of SEQ ID NO. 1/SEQ ID NO. 3) as cetuximab (Erbitux®) which has at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-?(1,3)-Gal.Type: ApplicationFiled: January 10, 2017Publication date: August 31, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Jian Cao, Jeffrey Su
-
Publication number: 20170247443Abstract: There is disclosed a chimeric infliximab-like monoclonal antibody having at least 80% NANA glycosylation terminal sialic acid and a glycosylation pattern of Gal-?(2,3/6)-Gal that binds to tumor necrosis factor alpha (TNF). The disclosed infliximab-like monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of SEQ ID NO. 1/SEQ ID NO. 2) as infliximab (Remicade®) which has at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-?(1,3)-Gal.Type: ApplicationFiled: January 10, 2017Publication date: August 31, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Jian Cao, Jeffrey Su
-
Publication number: 20170063826Abstract: A processing device executing a data feed service performs a first query of a repository of data feed entries. The processing device determines, based on the first query, that a first data feed entry comprises a schedule to provide data from a first data feed of a first data source to a first device in an upcoming first time period, wherein the first data feed entry identifies the first data source, a first data type associated with the first data source, the first time period, and the first device. The processing device sends, to the first data source, a request for first data having the first data type and then receives the first data. The processing device sends the first data to the first device in the first time period.Type: ApplicationFiled: August 23, 2016Publication date: March 2, 2017Inventors: Sudha Sundaresan, Vadym Byelov, Sulagna Bal, Jeffrey Su
-
Publication number: 20140279811Abstract: The present disclosure provides apparatus, systems, and methods for crowdsourcing domain specific intelligence. The disclosed crowdsourcing mechanism can receive domain specific intelligence as a data processing rule module. For example, a data analytics system can request a crowd of software developers to provide a data processing rule module tailored to process a particular type of information from a particular domain. When the data analytics system receives the data processing rule module from one of the software developers for the particular domain, the data analytics system can use the received data processing rule module to process information associated with the particular domain.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Factual, Inc.Inventors: Jeffrey SU, Boris SHIMANOVSKY
-
Publication number: 20070004008Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: ApplicationFiled: July 25, 2006Publication date: January 4, 2007Applicants: Human Genome Sciences, Inc., Auckland Uniservices, LimitedInventors: Jian Ni, Craig Rosen, Reiner Gentz, Jeffrey Su, Geoffrey Krissansen, Ping Feng
-
Publication number: 20060073573Abstract: Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: ApplicationFiled: October 6, 2005Publication date: April 6, 2006Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner Gentz, Guo-Liang Yu, Jeffrey Su, Patrick Dillon
-
Patent number: 6908986Abstract: Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: GrantFiled: May 10, 2002Date of Patent: June 21, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Haodong Li, Jeffrey Su
-
Publication number: 20050119457Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: ApplicationFiled: December 10, 2002Publication date: June 2, 2005Applicants: Human Genome Sciences, Inc., Auckland Uniservices, LimitedInventors: Jian Ni, Craig Rosen, Reiner Gentz, Jeffrey Su, Geoffrey Krissansen, Ping Feng
-
Publication number: 20050069945Abstract: Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.Type: ApplicationFiled: November 23, 2004Publication date: March 31, 2005Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Pedro Alfonso, Reiner Gentz, Jeffrey Su
-
Publication number: 20050019834Abstract: Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: ApplicationFiled: September 8, 2004Publication date: January 27, 2005Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Haodong Li, Jeffrey Su
-
Publication number: 20040198957Abstract: A method for removing endotoxin contaminants from protein solutions using hydrophobic charge induction chromatography sorbents. The methods comprise adjusting the ph of a protein solution to a pH of from about 8.0 to about 9.0, binding the protein to a hydrophobic charge induction chromatography sorbent; and eluting the protein from the sorbent using an elution buffer having a pH of from about 3.0 about 5.0. The method is particularly useful for removing endotoxin contaminants from antibody compositions.Type: ApplicationFiled: February 27, 2004Publication date: October 7, 2004Inventors: Inna Way, Simon Hoffenberg, Taeha An, Jeffrey Su
-
Patent number: 6593011Abstract: A light emitting diode and a method for making the same are proposed. The LED comprises an inorganic phosphor, a silicon compound and an organic glue. The silicon compound has one side being completely or partially C1-C6 alkyl oxide reacted with the inorganic phosphor to modify the surface property of the inorganic phosphor and another side being a functional group selected from a group consisting of epoxy, C1-C6 alkyl, phenyl, amino. The inorganic phosphor with modified surface property can be uniformly mixed in the glue and less deposition is produced.Type: GrantFiled: July 24, 2001Date of Patent: July 15, 2003Assignee: Lite-On Electronics, Inc.Inventors: Ru-Shi Liu, Chien-Yuan Wang, Ting-Shan Chan, Jeffrey Su, Michael Hsing
-
Publication number: 20030099859Abstract: A light emitting diode and a method for making the same are proposed. The LED comprises an inorganic phosphor, a silicon compound and an organic glue. The silicon compound has one side being completely or partially C1-C6 alkyl oxide reacted with the inorganic phosphor to modify the surface property of the inorganic phosphor and another side being a functional group selected from a group consisting of epoxy, C1-C6 alkyl, phenyl, amino. The inorganic phosphor with modified surface property can be uniformly mixed in the glue and less deposition is produced.Type: ApplicationFiled: July 24, 2001Publication date: May 29, 2003Inventors: Ru-Shi Liu, Chien-Yuan Wang, Ting-Shan Chan, Jeffrey Su, Michael Hsing
-
Publication number: 20020150994Abstract: Human chemokine alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: ApplicationFiled: May 10, 2002Publication date: October 17, 2002Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Haodong Li, Jeffrey Su
-
Publication number: 20020119528Abstract: Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: ApplicationFiled: November 7, 2001Publication date: August 29, 2002Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner Gentz, Guo-Liang Yu, Jeffrey Su, Patrick J. Dillon
-
Patent number: 6410268Abstract: Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: GrantFiled: March 18, 1997Date of Patent: June 25, 2002Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Haodong Li, Jeffrey Su
-
Patent number: 5952197Abstract: Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.Type: GrantFiled: March 5, 1997Date of Patent: September 14, 1999Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner Gentz, Guo-Liang Yu, Jeffrey Su, Patrick J. Dillon